← Eichor
Study identifier: NCT06736678 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Patients

Condition: Pancreatic Cancer · Neoadjuvant Chemoradiotherapy · Immunonutrition  ·  Sponsor: Sun Yat-sen University

PhaseNA
Planned participants98
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

A prospective, single-arm clinical trial is conducted to investigate the role of oral immunonutrion in reducing acute toxicity after neoadjuvant chemoradiotherapy among pancreatic cancer patients.

This description comes directly from the study's public registry record.

Talk to the study team

Weiwei Xiao  ·  +86 020 8734 0951  ·  xiaoww@sysucc.org.cn

Liping Chen  ·  +86 020 87340767  ·  chenlp@sysucc.org.cn

Always discuss trial participation with your own doctor first.

Locations (2)

Sun Yat-sen University Cancer CenterGuangzhou, Guangdong, ChinaRecruiting
Sun Yat-sen University Cancer CenterGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06736678